Acquisitions Spur Amedisys’ Hospice Growth

Amedisys Inc. (NASDAQ: AMED) is continuing to use acquisitions to build up its hospice footprint as the company braces for disruption to its home health care business stemming from the forthcoming transition to the patient driven groupings model (PDGM).  In the third quarter of 2019 Amedisys hospice segment revenue rose to $162 million, a 57% […]

Hospice M&A Market Going Strong in 2019

All signs point to a strong showing for hospice mergers and acquisitions through the year and into 2020 as companies and investors shy away from home health in anticipation of potential fallout from the forthcoming patient-driven groupings (PDGM) model. Eight hospice acquisitions took place during the first quarter of 2019, up from seven transactions during […]

Amedisys to ‘Feed the Beast’ for Hospice Segment Growth

Amedisys Inc., (NASDAQ: AMED),the third largest provider of hospice and home health in the United States, is prioritizing expansion of its hospice footprint through acquisitions and de novo activity, as the company cools down its home health care acquisition efforts due to uncertainties regarding the patient driven groupings model (PDGM). A focus on hospice growth […]

Rising Admissions Drive Amedisys Q1 Hospice Results

Rising hospice admission numbers led Baton Rouge, La.-based Amedisys Inc. (NASDAQ: AMED) to robust earnings in the first quarter of 2019. The rise in admissions includes both same-store and those associated with acquisitions. Same-store hospice admissions for Q1 2019 rose 5% to 9,711 patients, up from 6,933 in the first quarter of 2018. Average daily […]